Supplementary Materials

Supplementary Figure 1 The overall study design of the Anhui Lifestyle Validation Study.

Supplementary Table 1 The characteristics of participants according to urinary alkylresorcinols metabolites concentrations at baseline and after 1-year of follow-up in Huoshan, China.

Supplementary Table 2 Subgroup analysis on the association between urinary total alkylresorcinols metabolites and body fat measures in one-year longitudinal repeated-measures in Huoshan, China.

Supplementary Table 3 Subgroup analysis on the association between the average concentrations of urinary total alkylresorcinols metabolites and fat measures after 1-year of follow-up in Huoshan, China.



Supplementary Figure 1 The overall study design of the Anhui Lifestyle Validation Study. FFQ, food frequency questionnaire.

	DHPPA at baseline			DH	DHBA at baseline			DHPPA after 1-year of follow-up			DHBA after 1-year of follow-up		
Characteristic	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	Tertile	
	1	2	3	1	2	3	1	2	3	1	2	3	
No. of participants	102	102	102	102	102	102	102	102	102	102	102	102	
Age*, years	48.2	47.4	50.2	48.5	47.0	50.4	46.6	50.8	51.6	47.6	49.6	51.8	
	(14.3)	(14.2)	(16.1)	(14.5)	(15.2)	(14.9)	(15.8)	(15.6)	(12.7)	(16.2)	(15.4)	(12.7)	
Female ^{§§} , %	50.7	64.2	51.4	41.8	58.4	65.1	56.7	50.9	56.1	44.1	63.4	59.5	
household per capita income*,	%												
<10000 Yuan	29.9	48.9	30.9	24.4	45.5	32.4	28.6	19.6	25.6	24.0	19.3	20.9	
≥10000 Yuan	70.1	51.1	69.1	75.6	54.5	67.6	71.4	80.4	74.4	76.0	80.7	79.1	
Educational level, %													
Primary school or below	34.6	45.2	50.2	36.2	49.8	37.3	43.6	35.0	42.5	36.7	44.5	36.4	
Junior high school	27.8	26.7	24.1	26.2	27.5	29.1	27.0	32.5	32.4	29.6	29.8	34.5	
Senior high school or above	37.6	28.1	25.7	37.6	22.7	33.6	29.4	32.4	25.1	33.7	25.7	29.1	
Current tea drinkers** [‡] , %	42.8	37.4	63.3	50.4	44.1	47.1	39.8	54.6	62.9	43.9	52.9	56.8	
Current smokers, %	16.2	18.9	22.2	31.0	21.6	16.1	17.3	20.1	28.8	30.0	14.8	26.5	
Current drinkers*, %	24.8	10.9	22.9	24.5	18.3	14.4	12.9	17.2	18.9	18.6	16.5	12.7	
Diabetes, %	8.5	10.4	15.1	12.4	11.8	10.7	21.1	6.1	18.7	11.9	9.2	18.3	
Hypertension, %	51.1	45.6	53.1	50.8	57.4	44.6	47.4	52.7	47.3	50.3	48.5	48.2	
Physical activities													
	141	143	154	148	145	141	157	139	144	136	145	144	
METS-h/week	(98-	(108-	(93-	(111-	(101-	(92-	(108-	(90-	(96-	(88-	(106-	(96-	
	194)	199)	202)	199)	212)	190)	215)	200)	202)	193)	227)	206)	
	2062	2139	2219	2334	2026	2080	1872	2104	1788	2005	1992	1756	
Total energy intake ^{†§} , kcal/d	(1691-	(1646-	(1621-	(1786-	(1590-	(1619-	(1539-	(1617-	(1432-	(1631-	(1596-	(1425-	
	2695)	2852)	2799)	2933)	2573)	2682)	2498)	2457)	2558)	2511)	2595)	2294)	
DASH scores	24	24	24	24	24	24	24	24	24	23	24	24	
DASH scores	(22-27)	(22-26)	(21-27)	(22-27)	(22-27)	(22-26)	(21-26)	(22-26)	(21-26)	(21-26)	(22-27)	(22-26)	

Supplementary Table 1 The characteristics of participants according to urinary alkylresorcinols metabolites concentrations at baseline and after 1-year of follow-up in Huoshan, China^a

Abbreviations: DHPPA, 3-(3,5-Dihydroxyphenyl)-1-propanoic acid; DHBA, 3,5-dihydroxybenzoic acid; METS, metabolic equivalent tasks; DASH, dietary approaches to stop hypertension.

^aVariables were adjusted for age except for age and alkylresorcinols metabolites. Continuous variables were expressed as mean (standard deviation) or median (interquartile range) according to the distribution of the variables, while categorical variables are presented as percentage. *P* values were calculated from the one-way analysis of variance or Kruskal-Wallis test for continuous variables and χ^2 test for categorical variables. First urinary DHPPA: **P* value < 0.05, ***P* value < 0.01; First urinary DHBA: †*P* value < 0.05, ††*P* value <

0.01; Second urinary DHPPA: P value < 0.05, P value < 0.01; Second urinary DHBA: P value < 0.05, P value < 0.01.

body fat measures	Age		- D -	Sex		D	Physical activity		D	Total energy intake		_ D
	<60	≥60	- Γ interaction	Male	Female	P interaction	Low ^a	High ^b	r interaction	Low ^a	High ^b	Γ interaction
No. of participants	460	152		277	335		305	307		306	306	
	-0.07	0.07		-0.05	-0.31		0.09	-0.56		-0.08	-0.26	
WC	(-0.45,	(-0.78,	0.616	(-0.43,	(-0.82,	0.881	(-0.39,	(-1.13,	0.126	(-0.70,	(-0.79,	0.687
	0.30)	0.93)		0.33)	0.21)		0.56)	0.02)		0.55)	0.28)	
	0.05	-0.38		-0.03	0.10		-0.08	-0.44		-0.01	-0.40	
HC	(-0.37,	(-0.96,	0.125	(-0.48,	(-0.35,	0.404	(-0.72,	(-0.84,	0.982	(-0.35,	(-1.05,	0.797
	0.48)	0.21)		0.42)	0.54)		0.57)	-0.03)		0.34)	0.26)	
	-0.47	0.38		-0.30	-0.39		0.03	-0.22		0.05	-0.31	
WHR	(-0.75,	(-0.39,	0.227	(-0.78,	(-0.95,	0.467	(-0.58,	(-0.64,	0.063	(-0.47,	(-0.91,	0.379
	0.14)	1.15)		0.19)	0.16)		0.64)	0.19)		0.57)	0.30)	
	-0.16	-0.50		-0.42	-0.18		-0.36	-0.41		-0.40	-0.23	
BMI	(-0.47,	(-1.16,	0.099	(-0.81,	(-0.58,	0.397	(-0.81,	(-0.98,	0.867	(-0.89,	(-0.72,	0.559
	0.15)	0.17)		-0.03)	0.21)		0.09)	0.16)		0.09)	0.27)	
	-0.22	-0.13		-0.36	-0.18		-0.33	-0.33		-0.45	-0.19	
Weight	(-0.50,	(-0.62,	0.953	(-0.66,	(-0.54,	0.372	(-0.69,	(-0.80,	0.370	(-0.94,	(-0.56,	0.270
-	0.05)	0.36)		-0.05)	0.18)		0.02)	0.15)		0.04)	0.19)	

Supplementary Table 2 Subgroup analysis on the association between urinary total alkylresorcinols metabolites and body fat measures in one-year longitudinal repeatedmeasures in Huoshan, China.

Abbreviations: WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BMI, body mass index.

Data was presented as percentage changes and 95% confidence intervals (CIs) in obesity markers for each 1 μ g/g creatinine increase in urinary total alkylresorcinols metabolites, expressed as (exp(β)-1) × 100%. Covariates adjusted in the model was the same as those in Table 2 (see Table 2 footnote). Of note, variables examined in this table was not adjusted. Variables were log transformed.

^aLow: less than the median; ^bHigh: equal to or greater than the median.

fat measures -	Age		D	Sex		D	Physical activity		D	Total energy intake		D
	<60	≥60	P interaction	Male	Female	r interaction	Low ^a	High ^b	r interaction	Low ^a	High ^b	r interaction
No. of participants	227	79		139	167		152	154		153	153	
	-4.15	1.75		-2.46	-5.70		-4.23	-3.75		-4.65	-3.75	
BFM	(-8.07,	(-6.76,	0.943	(-7.76,	(-10.48,	0.222	(-8.89,	(-8.43,	0.668	(-9.98,	(-8.43,	0.531
	-0.06)	11.04)		3.13)	-0.67)		0.67)	1.18)		0.98)	1.18)	
	-1.99	-0.57		-1.03	-3.97		-3.03	-2.09		-2.77	-2.09	
PBF	(-4.76,	(-6.45,	0.520	(-4.92,	(-7.05,	0.133	(-5.96,	(-5.61,	0.313	(-6.30,	(-5.61,	0.427
	0.87)	5.68)		3.01)	-0.80)		0.00)	1.55)		0.89)	1.55)	
	-6.36	2.88		-3.44	-7.32		-5.43	-5.51		-5.48	-5.51	
VFL	(-11.08,	(-7.37,	0.531	(-9.50,	(-13.31,	0.264	(-11.01,	(-11.13,	0.811	(-11.88,	(-11.13,	0.720
	-1.40)	14.25)		3.02)	-0.91)		0.50)	0.47)		1.39)	0.47)	
	-2.81	1.56		-2.21	-2.18		-1.52	-2.88		-2.48	-2.88	
CAP	(-4.84,	(-2.91,	0.208	(-4.65,	(-5.04,	0.948	(-3.88,	(-5.29,	0.221	(-5.25,	(-5.29,	0.627
	-0.73)	6.24)		0.29)	0.77)		0.91)	-0.41)		0.37)	-0.41)	

Supplementary Table 3 Subgroup analysis on the association between the average concentrations of urinary total alkylresorcinols metabolites and fat measures after 1-year of follow-up in Huoshan, China.

Abbreviations: BFM, body fat mass; PBF, percent body fat; VFL, visceral fat level; CAP, controlled attenuation parameter.

Data was presented as percentage changes and 95% confidence intervals (CIs) in obesity markers for each 1 μ g/g creatinine increase in urinary total alkylresorcinols metabolites, expressed as (exp(β)-1) × 100%. Covariates adjusted in the model was the same as those in Table 3 (see Table 3 footnote). Of note, variables examined in this table was not adjusted. Variables were log transformed.

^aLow: less than the median; ^bHigh: equal to or greater than the median.